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Cardiovascular diseases (CVD) are the foremost cause of death worldwide. The main 
risk factor for CVD is uncontrolled hypertension (HTN). The prescription of only 
anti-hypertensive regimens in the management of HTN is becoming more challenging 
due to the high cost and adverse effects linked to the persistent usage of the drugs. 
Eighteen participants completed the study by consuming 2g of Hibiscus sabdariffa or 
oolong tea twice daily for six weeks. We lost an additional twelve participants in the 
study due to the COVID-19 pandemic. Central arterial stiffness was analyzed as 
cfPWV using applanation tonometry technique. The HS tea intervention (n=11) had a 
significant positive effect on SBP (P =0.02), DBP (P =0.001) and HR (P =0.03). Also, the 
HS tea consumption led to a non-significant (p=0.44) reduction in cfPWV (-0.5m/
s) when compared to control tea (+0.3m/s). Although, the decease in cfPWV could 




Recently, there have been drastic changes in the approach used in the treatment of 
various diseases, including high blood pressure and other cardiovascular diseases. The 
advent of several complementary alternative therapies has been proven to be very effective 
in lowering blood pressure, as well as reducing the potential risks of developing 
cardiovascular diseases (CVDs) (Whelton et al., 2018). According to the recent trends in 
the use of herbal tea as an alternative therapy in the treatment of hypertension (Mittal & 
Singh, 2010; Tabassum & Ahmad, 2011), the use of Hibiscus sabdariffa (Hs) tea might 
offer a cost-effective alternative to reduce the socio-economic burden associated with the 
treatment of hypertension, especially in the poorer states of the US, and in developing and 
low-income countries (where insufficient treatment has been a major contributing factor to 
the high prevalence of hypertension and other CVDs). The treatment of hypertensive 
individuals with only the available conventional anti-hypertensive regimens is becoming 
more challenging due to the high cost of the drugs, incomplete adherence to daily intake of 
pills, combination therapy to achieve maximum drug effect, and undesirable adverse 
effects associated with prolonged usage of different drug regimens (August, 2004; Susalit 
et al., 2011; Wang & Xiong, 2012). 
1.1 Hypertension 
The World Health Organization (WHO, 2013) defined hypertension as a chronic 
condition that is characterized by a continual rise in the pressure at which blood flows in 
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the blood vessels, which makes it hard for the heart to pump blood into the circulation. 
Diagnosis of hypertension is established when an individual has systolic blood pressure 
(SBP) of ≥ 130mmHg and diastolic blood pressure (DBP) of ≥80mmHg, this is in 
accordance with the guidelines formulated by the American Heart Association (AHA). 
(Whelton et al., 2018). High blood pressure is one of the leading risk factors that contribute 
to a high prevalence of cardiovascular diseases (CVDs) worldwide. Cardiovascular 
diseases encompass several groups of other heart diseases such as ischemic heart disease 
(IHD), coronary artery disease (CAD), congestive heart failure, cerebrovascular disease, 
and myocardial infarction (MI) (Mendis et al., 2011). Uncontrolled high blood pressure 
has also been attributed to be the leading cause of chronic renal failure in most of the 
countries with a high prevalence of hypertension (Pierdomenico et al., 2009). 
Implementing lifestyle changes, such as dietary intervention with conventional therapy, 
can help delay or mitigates increases in blood pressure, thereby decreasing the risk of 
developing CVD and organ damage associated with poorly controlled high blood pressure. 
1.1.1 Causes of hypertension 
Hypertension (HTN) can be classified as either; primary/essential or secondary 
HTN based on the causative factors. Currently, about 90-95% of cases of hypertension in 
adults are primary HTN, while only 5% of cases are classified as secondary HTN. Primary 
or essential type HTN is usually of unknown etiology and can sometimes be referred to as 
idiopathic. However, several associated risk factors have been implicated in the 
development of HTN, and these factors have been broadly categorized as either genetic or 
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environmental factors. Genetic alterations: overexpression or underexpression of specific 
genes have been reported as an unchangeable factor associated with HTN. High blood 
pressure can be inherited and run in families, with an incidence of heritability of about 15-
30% for DBP and 15-40% for SBP ((Padmanabhan, Aman, & Dominiczak, 2019). 
Similarly, certain genetic disorders such as Liddle’s syndrome (autosomal dominant 
mutation in sodium channel), a mutation in the gene that results in excess production of 
cortisol, glucocorticoid-remediable aldosteronism (GRA) have been identified in the 
development of genetic HTN (Levanovich, Diaczok, & Rossi, 2019).  
Environmental factors linked to HTN include aging, obesity, high consumption of 
alcohol, excess dietary salt intake, stressful lifestyle, potassium deficiency sedentary 
lifestyle, chronic intake of caffeine and other sympathomimetic agents (i.e., exciting the 
sympathetic nervous system) which are all classified as hypertensinogenic factors. An 
increase in body weight, specifically excess fat in the abdomen is one of the most common 
hypertensinogenic factors. Several studies have reported a positive correlation between 
weight gain and increased BP while controlling body weight in healthy individuals can 
significantly reduce both SBP and DBP (Rafiee, Khaledi, Madmoli, Zafari, & Lotfizadeh, 
2019). Obesity has been reportedly linked to type II diabetes mellitus (insulin resistance), 
hyperlipidemia, deposition of fat droplets in the arterial wall (atherosclerosis), and left 
ventricular hypertrophy; which can all result in the development of HTN and other CVDs. 
Although, the mechanism of obesity-induced HTN has not been clearly proven; however, 
an increase in plasma volume in overweight individuals can subsequently increase cardiac 
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output and BP. Similarly, possible vasoconstriction in obese individuals and enhanced 
renin release from the kidney can both increase sympathetic nerve activity (Tesauro & 
Cardillo, 2011). 
Secondary HTN, which accounts for only about 5-10% cases of global HTN, occurs 
due to an underlying medical condition that is usually reversible once the triggering 
medical condition is treated promptly. The diagnosis and onset of secondary HTN vary by 
age and clinical symptoms; however, secondary HTN has been reported to be more 
prevalent among younger adults within the age of 18-40 years (Charles, Triscott, & Dobbs, 
2017). The associated causes of secondary HTN usually vary between adults and 
preadolescent children; although, medical conditions such as kidney disease, renovascular 
disease, hyperlipidemia, diabetes mellitus, pheochromocytoma (tumor producing excess 
catecholamines), obstructive sleep apnea, and pregnancy are linked to secondary HTN 
across all adult ages. Other uncommon etiology of secondary HTN includes medications 
such as oral contraceptives, non-steroidal anti-inflammatory drugs (NSAIDs), hormonal 
therapy, several chemotherapeutic drugs, and some recreational drugs (Grossman & 
Messerli, 2012).   
1.1.2 Prevalence of hypertension 
The recent redefinition of HTN in 2017 and 2018 by ACC/AHA and European 
Society of Hypertension (ESH), respectively, from 140/80mmHg to 130/80 mmHg, which 
was formerly classified as prehypertensive, has greatly increased the prevalence of HTN 
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in the US and other countries in the world. The current global prevalence of HTN among 
young (>45 years) and older adults before the reclassification by AHA/ESH is about 30-
35%; however, while applying the updated definition of HTN, the global prevalence in 
adults is now > 60% (Touyz, 2019). The current guideline suggested prompt and intense 
implementation of treatment to lower the blood pressure, especially SBP below 140 
mmHg, and this has been associated with a significant reduction in mortality rate from 
stroke and other  CVDs (Salam et al., 2019). 
The influence of geographical regions classified as developed or developing 
countries on the global prevalence of HTN cannot be underestimated, although factors such 
as genetics and environmental factors have a significant influence on the geographical 
distribution of HTN.  According to a recent report of the world health organization (WHO, 
2013), prevalence rate of HTN is high (about 46%) in Africa and other developing 
countries, while low prevalence rate of (35%) was reported by WHO in America region 
(Al Kibria, 2019). Ethnicity or race has also been reportedly shown to influence the global 
prevalence of HTN. The high incidence rate of HTN among Latinos, Asians, and African 
Americans living in the US has been reported when compared with Caucasians. The high 
blood pressure among non-Caucasians might be related to several factors such as 
socioeconomic status, high dietary salt intake, heredity, and low level of renin-angiotensin 
has been detected in the plasma of African American. 
Gender and age have been reportedly shown to affect the awareness and 
management of HTN especially among the young adults within the age of 18 to 54 years 
when compared with older adults of age >55 years, thus influencing the global prevalence 
of HTN (Tadic, Cuspidi, Grassi, & Ivanovic, 2019). The pathophysiology differences 
associated with gender are related to variation in sex hormones, components of the renin-
angiotensin-aldosterone system (RAAS), and the sympathetic nervous and nitric oxide 
systems (EUGenMed et al., 2016). The cardioprotective effect of estrogen, most notably 
in premenopausal women, can be related to the low incidence of HTN and reduce the risk 
of developing CVDs when compared with men within the same age range. Estrogen plays 
a vital role in the activation of nitric oxide (NO), which is a potent vasodilator, inhibits the 
activation sympathetic nervous system and decreasing the activity of RAAS by blunting 
the production of angiotensin-converting enzyme (ACE) which blocks the formation of 
angiotensin II (Ang II). Blocking Ang II, which is a potent vasoconstrictor, is highly 
essential in the regulation of blood pressure. However, male sex hormone androgens can 
increase the synthesis of angiotensinogen II from the liver cells, which subsequently result 
in increased production of Ang II. Similarly, androgens can also enhance the reabsorption 
of sodium ion from the proximal convoluted tubules of the kidney via the androgen 
receptors, resulting in increased vasoconstriction and high blood pressure(Song, Ma, 
Wang, Chen, & Zhong, 2019).  
Several contributing factors, such as the high incidence of smoking and 
hyperlipidemia, which are more prevalent in men, can account for gender differences in 
the prevalence of hypertension. Variations in the pharmacokinetics and pharmacodynamics 
response to antihypertensive drugs between men and women could also account for gender 
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differences in the prevalence of HTN. Women are more likely to develop adverse drug 
effects than men, alteration in drug metabolism by female sex hormones could reduce the 
clinical response of women to antihypertensives (Ueno & Sato, 2012). 
1.1.3  Treatment of Hypertension 
According to the recent guidelines in the diagnosis and treatment of HTN by 
ACC/AHA, recommendations for treatment have been revised based on the new directions 
that redefined HTN as SBP ≥ 130mmHg and DBP ≥ 80mmHg. However, not all individuals 
who are classified as being hypertensive based on recent ACC/AHA definition are 
recommended to commence treatment with antihypertensive drugs. Eligibility for 
antihypertensive recommendation is based on age (>65 years) and the presence of 
preexisting clinical medical conditions, such as diabetes mellitus, chronic renal disease, 
atherosclerosis, and other CVDs. At the same time, dietary/lifestyle modifications are 
recommended to hypertensive patients who do not meet the eligibility criteria (Khera et al., 
2018). 
Several antihypertensive therapies, ranging from ACE inhibitors, calcium channel 
blockers, beta-blockers, α-blockers, vasodilators, and diuretics have helped to normalize 
blood pressure in individuals with high blood pressure. However, despite the availability 
of different types of antihypertensive drugs, only about 36 million hypertensive individuals 
out of 1.4 billion of affected people globally, had their blood pressure controlled (Control 
& Prevention, 2012). Studies have shown that about 40-60% of individuals with 
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uncontrolled BP were due to incomplete adherence or non-compliance to drugs, while 
others were due to lack of awareness (Control & Prevention, 2012). High prevalence of 
uncontrolled BP among hypertensive individuals has contributed to increased risk of 
developing cardiovascular disease, most notably in the developing countries where socio-
economic burden has affected the affordability of high costs of antihypertensive drugs. 
Similarly, adverse effects associated with prolonged use of a single drug type, or 
combination regimen, have been a great challenge in the management of HTN.  Recently, 
the use of specific antihypertensive drugs has been linked with the development of cancer, 
although many of the links are still controversial. For instance, treatment with some 
calcium-calcium channel blockers has been associated with the incidence of breast cancer 
(Wright et al., 2017), while the use of common diuretics; hydrochlorothiazide (HCT) and 
thiazide have been linked with skin cancers and ovarian cancers respectively (Huang et al., 
2016; Pedersen et al., 2018). 
1.2 Pathophysiology of hypertension. 
Interaction between several mechanisms that affect the vascular system, arterial 
system, sodium and fluid balance in the body are all implicated in the pathogenesis of HTN. 
The role of an arterial system comprising of the aorta (largest arteries), small arteries, and 
the microcirculation (arterioles and capillaries) in the development of HTN cannot be 
underestimated. Small arteries and arterioles with a diameter (<300µm) are highly resistant 
vessels that play a significant role in the regulation of BP. According to Poiseuille’s law, 
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out of the three major factors that determine the resistance to blood flow in the vessels, the 
diameter of vessels is the essential factor. The primary mechanisms that are involved in the 
pathogenesis of HTN are discussed below. 
1.2.1 Autonomic nervous system 
Alteration in the autonomic nervous system, which consists of both the sympathetic 
nervous system (SNS) and parasympathetic nervous system (PNS), plays a crucial role in 
the regulation of BP. Stimulation of either SNS or PNS, which depends on the type of 
receptors (α or β) that binds the neurotransmitters (either catecholamines or acetylcholine), 
can cause alteration in heart rate and blood vessel tone. Activation of SNS is usually 
excitatory, causing both increases in heart rate and vasoconstriction, which are essential 
factors that precipitate an increase in BP, while PNS has an inhibitory effect on heart rate. 
Activation of sympathetic nervous activity to the heart, skeletal muscles, blood 
vessels, and kidney contributes to a rapid increase in BP and may lead to subsequent 
development of HTN, cardiac arrhythmias, atherosclerosis, left ventricular hypertrophy 
and other CVDs. The SNS is activated by several factors such as obstructive sleep apnea 
(OSA), genetics (about 50% of SNS over-reactivity can be inherited), stress, increase 
dietary calorie intake, obesity, chronic exposure to caffeine, and some other 
sympathomimetic agents (Grassi & Ram, 2016).  Similarly, degrees of fat distribution in 
the body and general obesity has been associated with enhanced SNS activity. 
Microneurography analysis has confirmed the evidence of epinephrine spillover in the 
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plasma with the high concentration deposited in the kidney, thus justifying the correlation 
between the obesity, SNA activation, and HTN (Seravalle & Grassi, 2017).  
1.2.2 Alteration in Vascular smooth muscle cell 
All the blood vessels composed of vascular smooth muscle cells (VSMC), except 
for the capillaries. The VSMCs are located in the middle part (tunica media) in the structure 
of the blood vessel. The layers of VSMC are usually thicker in arteries when compared to 
the veins due to the pressure of blood flowing through the venous bed. The VSMC cells 
are differentiated and formed from the neural crest cells of main aorta and arteries; 
however, alterations in the synthesis of the VSMC, such as immature proliferation, growth, 
and migration have been implicated in the pathogenesis of HTN (Fisher, 2010; Kietadisorn, 
Juni, & Moens, 2012). The proliferation of VSMCs, which can either be an abnormal 
increase in the size of the cells (hypertrophy) or increase in the number of cells 
(hyperplasia), or presence of both pathological changes have been linked to abnormal 
growth in VSMC (Marx, Totary-Jain, & Marks, 2011).   
Several stimulating growth factors, which are called mitogens, such as endothelin, 
thrombin, interleukin-1, platelet-derived growth factor (PDGF), vasopressin, serotonin, 
bradykinin, and angiotensin II are responsible for contraction of VSMC (Bacakova et al., 
2018).  The constriction of VSMCs, mediated by the contractile agonists listed above, 
contributes significantly to a decrease in the diameter of blood vessels. Considering 
Poiseuille’s law, three factors, which are vessel diameter, vessel length, and blood 
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viscosity, determines the resistance to blood flow in the vessel. Decreases in diameter 
contribute majorly to increased peripheral resistance in blood vessels and subsequent 
increase in arterial blood pressure. 
1.2.3 Endothelial dysfunction 
The endothelial cells, which is a semi-permeable layer (located in the luminal parts 
of the blood vessel), often referred to as “tunica intima or tunica interna,” form direct 
contact with blood. Mechanical or biochemical damage to endothelial cells contributes to 
endothelial dysfunction and the pathogenesis of HTN. Increased production of harmful 
substances, such as free radicals (superoxide anions, hydroxyl ions, and other oxidants), in 
the blood and their attachment to the endothelium constitutes biochemical damage to the 
endothelium (Drummond, Selemidis, Griendling, & Sobey, 2011; Zeng, Villar, Yu, Zhou, 
& Jose, 2009). Damaged endothelium stimulates the activation of inflammatory cascades 
that leads to the production of certain substances such as platelet-derived growth factor 
(PDGF), nuclear factor kappa B (NF-kB), tumor necrosis factor (TNF), vascular cell 
adhesion molecules (VCAM), interleukins and other inflammatory cells that stimulate 
proliferation of VSMC, vasoconstriction and eventually HTN (Masi, Uliana, & Virdis, 
2019).  Endothelial cells also produce substances that mediate the dilation of blood vessels 
and vascular tone. Nitric oxide (NO), endothelial-derived hyperpolarizing factors, and 
prostacyclin are potent vasodilators, and decreased production or release of vasodilators 
from the endothelial cells can also cause endothelial dysfunction and thus contribute to the 
development of HTN (Daiber et al., 2019). 
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1.2.4 Renin-angiotensin-aldosterone system (RAAS).    
The RAAS system, which is considered both an endocrine and paracrine system, 
entails a series of hormonal cascades that exert its effect on renal function, maintenance of 
sodium/water balance, and physiological regulation of blood pressure. Pathological 
activation of RAAS in certain disease conditions plays a vital role in the pathogenesis of 
HTN.  The release of renin initiates the activation of RAAS, a glycoprotein secreted and 
stored in the juxtaglomerular cells (JG) of the nephron. It has been reported that JG cells 
also contain β1 adrenergic receptors, which can be stimulated by the sympathetic nervous 
system, thus inducing the release of renin from the JG cells. Signaling from macula densa 
cells due to deficiency of sodium ions and water imbalance can also stimulate the release 
of renin. Renin acts on its substrate called angiotensinogen, which is secreted mainly in the 
liver, converting it into an inactive peptide named angiotensin I (Ang I). Hydrolysis of Ang 
I by angiotensin-converting enzyme (ACE) forms angiotensin II (Ang II), which is a potent 
vasoconstrictor that mediates increased BP and organ damage associated with uncontrolled 
HTN (Mannelli, Rossi, Vanderriele, & Parenti, 2018). 
The Ang II acts by binding to its specific receptors to mediate its effect, two different 
types of receptors, angiotensin type I (AT1) and type II (AT2), have been identified. The 
binding of Ang II to the AT1 receptor mediates most of the effects of Ang II. Also, apart 
from the vasoconstriction effect of Ang II, it stimulates the release of aldosterone from the 
adrenal cortex. Aldosterone plays a crucial role in maintaining normal homeostasis by 
controlling sodium, potassium, and water balance in the body. Increased production of 
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aldosterone enhances the reabsorption and retention of sodium and water in the body, thus 
causing an increase in blood volume, blood pressure, and development of HTN 
(Provenzano & Sparks, 2019).  
1.3 Arterial stiffness 
1.3.1 The physiological role of Arteries 
The arterial system, especially the large arteries, perform a conduit function. The 
arteries in a healthy young adult individual deliver adequate oxygenated blood from the 
left ventricle of the heart to the systemic circulation. The conduit function of the arteries 
ensures the proper supply of blood to the peripheral organs and tissues in the body, and the 
efficiency of the conduit function depends on the distensibility and stretching ability of the 
large artery (aorta) to accommodate an increase in blood flow. This physiological 
stretching ability of the arteries when there is an increase in blood flow widens the diameter 
of arteries, decreases peripheral resistance, and thus controls mean arterial blood pressure 
(London & Guerin, 1999).  
Similarly, another interrelated function of the arteries is the ‘dampen function or 
cushion function’(Sun, 2015). During systole, only about 40% of the blood pumped out of 
the left ventricle is supplied to the organs and tissues. In contrast, the remaining blood is 
stored in the elastic arteries. The aorta recoils during diastole, squeezing the preserved 
blood into the peripheral tissues, thus ensuring continuous organ and tissue perfusion. This 
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recoil during diastole is also essential to perfuse cardiac muscle with oxygen-rich blood 
(W. W. Nichols et al., 2008).    
1.3.2 Pathophysiology of Arterial stiffness 
The Stiffening of the arteries termed “arteriosclerosis” occurs because of the 
alteration in the structure of the arterial wall. The arterial wall consists of smooth muscle 
cells, connective tissues (mainly elastin and collagen fibers), and fibrous tissue. The 
arrangement of elastin and collagen fibers varies according to the size of the arteries; the 
ratio of elastin to collagen is usually high in the aorta/large arteries when compared to 
peripheral arteries and arterioles (Wagenseil & Mecham, 2012). The Degenerative changes 
observed in the ECM of the tunica media part of the arteries, which is characterized by a 
reduction in the elastin/collagen ratio or viscoelastic properties of the artery is the primary 
pathophysiology that reflects arterial stiffness (London, Marchais, Guerin, & Pannier, 
2004). 
Contraction of the left ventricle during systole generates a wave called a pulse 
wave, which is palpable at the wrist or at the carotid artery of the neck (and along many 
other arteries that are near the skin’s surface). This wave produced during ventricular 
ejection is termed an incident wave, and the speed at which the waves travel away from 
the heart is called pulse wave velocity. The incident wave can be reflected at any point 
during the cardiac cycle, and the timing for the reflected waves depends significantly on 
the viscoelastic properties of the arteries (W. Nichols, 1998). Arterial stiffness can cause a 
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significant increase in the pulse wave velocity and untimely return of reflected wave during 
systole instead of diastole. In a healthy artery, the reflected wave should return to the heart 
during diastole to ensure a continuous supply of blood to coronary arteries, while the early 
return of the reflection wave during the systolic phase can augment the incident wave 
causing an increase in both pulse pressure and systolic blood pressure.  Figure 1.1 
illustrates the incident and refection waves, as well as hemodynamic changes in both 
normal and stiffened arteries. 
  Figure 1.1. (A) Aortic pressure waveform showing both forward traveling wave (incident 
wave) and reflected wave of an individual with a normal artery. (B) Aortic pressure 
16 
waveform in an individual with a stiffen artery where the summation of the incident wave 
and reflected wave had augmented the pulse pressure (Van Varik et al., 2012). 
1.3.2.1 Arterial Stiffness and Hypertension 
Arterial stiffness is commonly one of the first contributing mechanisms to the 
development of essential hypertension. Disruption in elastin, which is the major ECM 
component in the arterial wall, contributes mainly to arterial stiffness and HTN. The large 
arteries and aorta serve as capacitance vessels that distend and recoil during systole and 
diastole, respectively. However, a stiffened artery requires more pressure to stretch the 
arterial wall to pump blood to distal vessels and systemic circulation. The early return of 
reflected waves back to the aorta during the systolic phase increases the systolic pressure, 
especially in older individuals. In young individuals, PWV is relatively slow due to the late 
return of reflected wave at the diastolic phase of the cardiac cycle, thereby increasing the 
diastolic pressure.  
The importance of altered elastin in the development of arterial stiffness and HTN 
was confirmed by an animal model study where elastin was genetically knocked down in 
mice. Increased left ventricular pressure, and systolic pressure was observed in modified 
mice when compared with wild type mice (Wagenseil & Mecham, 2012). Arterial stiffness 
was also significantly increased in elastin-knocked out mice, and this preceded the 
observed blood pressure increase. Thus, early detection of increased PWV even before the 
development of high blood pressure can be a new clinical marker in the diagnosis of HTN 
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and CVDs. While developing a new therapeutic approach targeting the reduction of PWV 
and arterial stiffness can significantly reduce the high prevalence rate of HTN and CVDs. 
1.3.3 Measurements of Arterial Stiffness 
Evaluation of arterial blood pressure and pulse pressure at the brachial artery has 
been used as a predictor for the diagnosis of HTN and other cardiovascular diseases. 
Although brachial arterial blood pressure does not usually provide accurate analysis of the 
pressure in the aorta and large elastic arteries; thus measurements at the brachial artery are 
an indirect evaluation of arterial stiffness (Wagenseil & Mecham, 2012). In healthy 
individuals with normal arterial distensibility, their aortic blood pressure is usually lower 
than the systolic brachial pressure, because the aorta has higher distensibility than other 
large arteries. However, in certain circumstances, the brachial arterial blood pressure might 
be of the same value as the aortic blood pressure, thus providing an inconclusive marker 
of cardiovascular events. The rough and inaccurate measurement of arterial stiffness with 
the brachial artery has led to the discovery of several non-invasive methods, such as 
Doppler ultrasound, pressure transducer, photoplethysmography and magnetic resonance 
imaging (MRI), which can provide a more specific indication of arterial stiffness (Urbina 
et al., 2009).  
In-vivo measurement of arterial stiffness humans depends on the ratio of pressure 
changes in the arteries to the alteration in diameter at both diastolic and systolic phase of 
the cardiac cycle. Measuring aortic PWV by recording the pulse wave in the common 
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carotid arterial and femoral artery (cfPWV) has been reported as the standard method for 
in-vivo measurement of arterial stiffness in humans. The distance between the carotid and 
femoral arteries can be measured superficially with a measuring tape, while the pulse wave 
can be detected using applanation tonometry. The cfPWV is obtained from a distance/per 
unit time of the traveling wave between the two locations. Applanation tonometry, which 
makes use of computer software to record both the incident and reflected waves, has been 
proven to be a reliable diagnostic tool used in estimating arterial stiffness in clinical and 
research cardiovascular laboratories (Crilly, Coch, Bruce, Clark, & Williams, 2007).  
1.3.3.1  Applanation Tonometry 
Evaluating arterial stiffness by applanation tonometry involves two main 
techniques: pulse wave analysis (PWA) and pulse wave velocity (PWV). Mohamed first 
invented the use of the PWA technique to access arterial stiffness in 1872, where the 
pressure waveforms differences between central and peripheral arteries were analyzed 
(Mohamed, 1872). However, the current PWA involves the use of a tonometer to record 
the pulse waves of a specific artery. Most commonly, the radial artery and the waves are 
automatically analyzed by SphygmoCor computer software. This PWA gives an estimate 
of aortic blood pressure waveform when calibrated with individual brachial blood pressure, 
thus providing the estimates of central SBP, DBP, PP, and MAP.  Apart from the aortic 
blood pressure, aortic argumentation index (AIx) can also be obtained from the PWA. 
Figure 1.2 shows a sample report of PWV measured at the radial artery indicating the aortic 
blood pressure and AIx. The AIx means the augmented aortic systolic blood pressure 
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caused by the return of reflected waves at the aorta either at the systolic or diastolic phase, 
depending on the mechanical structure of the large arteries (Papaioannou et al., 2004). 
Also, the AIx has been reportedly linked to an individual’s heart rate, blood ejection time, 
and height.  Monitoring arterial stiffness using PWA can be used to provide useful 
information about cardiovascular events (Townsend et al., 2015).  
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Figure 1.2. Sample recordings of PWA of radial artery obtained from SphygmoCor 
applanation tonometry showing the aortic blood pressure (SBP, DBP, MAP, and PP) and 
the aortic augmentation indices.   
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Pulse wave velocity (PWV) involves the evaluation of the speed of pulse wave, 
which is automatically calculated based on the distance traveled by the wave from one 
point to another per unit time. Unlike the PWA, measurement of PWV by the SphygmoCor 
usually corresponds with the electrocardiogram (ECG) reading, specifically the R-wave of 
the ECG, which indicates the start of ejection of blood from the ventricles. The carotid and 
femoral arteries are the two points commonly used to estimate pulse wave velocity 
(cfPWV). Measurement involves placing a measuring tape to measure the superficial 
distance from the aorta (located at the suprasternal notch) to the carotid and femoral 
arteries, while time delay from the R-wave to the pulse arriving at the given palpated 
arterial site is measured by the tonometer placed on the respective arteries. The 
SphygmoCor computer software automatically utilizes the measured distance and time to 
evaluate the cfPWV (m/s). Figure 1.3 shows the sample report indicating the carotid-
femoral pressure pulse waves, ECG, and cfPWV. 
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Figure 1.3. Sample recording of cfPWV obtained from the automatic calculation of the 
distance from carotid and femoral sites for a delay time of pulse arrival after the respective 
R-waves.
1.3.4 Factors Influencing Arterial Stiffness. 
The extent of arterial distensibility depends greatly upon the composition of the 
blood vessels, most especially aorta and large arteries. Any factors either modifiable or 
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non-modifiable that alter the fundamental structure of blood vessels can result in stiffening 
of the arteries. The most important structural components include VSMC, collagen, and 
elastin. Aging is one of the essential non-modifiable independent risk factors that induce 
the development of arterial stiffness and HTN. An increase in age has been associated with 
altered ECM proteins in the blood vessel, such as calcification and fragmentation of elastin 
(decrease elastin) and accumulation of collagen, thus reducing the viscoelastic properties 
of the vessel wall. This structural disruption in ECM protein would reduce the dampening 
function of the arteries and increase PWV with a resultant increase in systolic blood 
pressure and pulse pressure. 
Several reports have shown the relationship between age and arterial stiffness 
(Franklin et al., 1997; Mitchell et al., 2004; Wen et al., 2015). The stiffness is usually more 
noticeable in the central artery and aorta when compared to muscular or peripheral arteries. 
Evidence has shown a strong correlation between age and carotid artery stiffness, while 
there was no correlation between femoral artery stiffness and age (W. Nichols, 2005; van 
der Heijden-Spek et al., 2000). Aortic and carotid PWV increases with age with an 
approximate value of about 0.1m/s every year with an estimate of almost 10% to 15% 
increase during ten years (W. Nichols, 2005). In addition to the alteration in viscoelastic 
properties of the vascular wall, the presence of metabolic syndrome and inflammation 
could also contribute to age-related arterial stiffness and HTN.  The presence of diseases 
such as type II diabetes, obesity, dyslipidemia, hyperglycemia, and end-stage renal disease 
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could promote vascular aging, stiffening of the arteries, and development of HTN (Ferreira, 
Schouten, Smulders, Twisk, & Stehouwer, 2012).  
Dietary modifications are one of the modifiable factors that can influence arterial 
stiffness. Consumption of alcoholic wine can induce a small but significant decrease in BP, 
AIx, PP, and PWV measured at the radial artery, while no significant hemodynamic 
changes were observed in participants exposed to non-alcoholic wine (Mahmud & Feely, 
2002). Similarly, chronic intake of caffeine, either in the form of a tablet or consumed in 
coffee can induce have been associated with an acute increase in AIx and SBP when 
compared with participants exposed to placebo or decaffeinated coffee (Waring, Goudsmit, 
Marwick, Webb, & Maxwell, 2003).  Other dietary modifications, such as high 
consumption of fish (Del Brutto, Mera, Peñaherrera, Peñaherrera, & Costa, 2018) and high 
intake of antioxidant vitamins most especially, vitamins A, C, D,  E and K (Mozos, Stoian, 
& Luca, 2017), have been shown to reduce arterial stiffness. 
Lifestyle medications is another modifiable factor that influences changes in arterial 
stiffness. Regular exercise either, aerobic endurance or resistance exercise, can induce a 
significant decrease in aortic PWV and carotid AIx when compared to individuals with a 
sedentary lifestyle (Mutter, Cooke, Saleh, Gomez, & Daskalopoulou, 2017). Cigarette 
smoking has also been associated with the development of CVDs. Both short- and long-
term smoking can induce endothelial dysfunction, thereby increasing arterial stiffness. 
Numerous studies have confirmed the effect of long and short-term smoking on arterial 
compliance among active smokers; however, in cases of short smoking, most significant 
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changes in arterial compliance are usually observed within the first five minutes after acute 
smoking (Kim et al., 2005; Xue et al., 2019).  Besides, passive smoking involving long 
term exposure to environmental air polluted with tobacco smoke has been associated with 
carotid arterial stiffness. However, this depends on the dose of exposed pollutant mixtures 
(Ljungman et al., 2018). 
1.4 Hibiscus sabdariffa. L 
Hibiscus sabdariffa. L (Hs) is an annual herb that belongs to family Malvaceae, and 
it is widely known in English as a roselle or red sorrel. The HS plant (figure 1.4) is a tropical 
shrub that is commonly grown in many tropical regions of the world, especially in South 
East Asia, India, America, Central and West Africa (Ngamjarus et al., 2010). Different 
parts of the hibiscus plant, leaves, flowers, and calyx are used medicinally for treatment of 
various health issues; however, fresh, or dried calyces of the flower are popularly used to 
produce hibiscus tea or sour tea.  The phytochemical and pharmacological analysis of Hs 
reviewed by several studies has shown the presence of bioactive compounds, which are 
mainly: polyphenols. 
Phytochemical analysis indicates the presence of five essential polyphenols in HS 
and other plant extracts: anthocyanins, flavonoids, anthocyanidins, phenolic and organic 
acids.  Anthocyanins have been identified as the significant polyphenols compound in the 
hibiscus plant, and they confer the red pigment to the calyces of the HS flower (Grajeda-
Iglesias et al., 2016). Four types of anthocyanins have been unearthed and are described 
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based on differences in the make-up of their chemical structure, these include Delphinidin 
(anthocyanidin), Delphinidin-3-sambubioside (hibiscin), Cyanidin -3-sambubioside, and 
Cyanidin-3,5- diglucoside. Both delphinidin-3-sambubioside and cyanidin-3-
sambubioside are the most effective anthocyanins in HS extract (Yang et al., 2009). 
Figure 1.4. Hibiscus sabdariffa L. flower showing the petals, stigma, and stamen.  
(Picture was taken at MTU greenhouse; photo credit: John Durocher).  
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1.4.1 Hibiscus sabdariffa. L and Blood Pressure. 
The beneficial effect of Hibiscus sabdariffa extracts on lowering blood pressure 
both in normotensives and hypertensives have been extensively reported in both human 
and animal studies. According to Inuwa et al, there was a significant reduction in SDP, 
DBP, mass of the left ventricle of the heart when the effects of HS extract on hypertension 
was observed on rats for about ten weeks, although they show no effect on heart rate (Inuwa 
et al., 2012). In another comprehensive report by Hopkins et al. (Hopkins, Lamm, Funk, & 
Ritenbaugh, 2013), HS extract showed an effective reduction in blood pressure in both 
hypertensive  and normotensive animals. Several clinical randomized human trials where 
dried calyxes of HS were brewed as tea, used as a juice, or directly as an extract on different 
populations have confirmed the hypotensive effect of HS. A randomized controlled trial 
(RCT), where hypertensive patients were exposed to 10g of dried HS extract per day, 
reported a substantial reduction in SBP and DBP after four weeks intervention period 
(McKay, Chen, Saltzman, & Blumberg, 2009). Similarly, the hypotensive effect of HS was 
compared with Lisinopril (a potent antihypertensive drug) in a double-blind controlled 
clinical trial. After four weeks intervention period, a similar reduction in BP was observed 
among participants exposed to Lisinopril and HS tea, thus confirming the effectiveness of 
HS extract as other pharmaceutical antihypertensive therapies (Herrera-Arellano et al., 
2007). 
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1.4.2 Antihypertensive mechanisms of Hibiscus sabdariffa. L 
The exact mechanism by which HS mediates a reduction in BP in humans is still 
unknown. Studies showing the three main antihypertensive mechanisms HS have been 
reported and are compared with the mechanisms of action of most of the generally used 
antihypertensive drugs. The identified mechanisms of action include; angiotensin-
converting enzyme inhibitors (ACE inhibitor), vasodilator, and diuretic properties 
(Alarcón-Alonso et al., 2012; Ojeda et al., 2010; Sarr et al., 2009). The anthocyanins, 
specifically delphinidin-3-sambubioside and cyanidin-3-sambubioside, are responsible for 
most of the mechanisms involved in lowering BP.  
1.4.2.1 Diuretic mechanism 
The HS can stimulate the release of nitric oxide which is a vasorelaxant from the 
endothelial lining of the blood vessels. The nitric oxide (NO) regulates the rate of blood 
flow to the kidney and glomerular filtration rate. The role of NO in normal function of the 
kidney has been linked with its ability to increase the reabsorption of sodium from the 
kidney tubules. The diuretic property of HS was assessed in an animal model and a 
randomized clinical trial, where a decrease in plasma concentration of sodium due to 
increased urinary excretion was observed in both hypertensive rats and patients with HBP 
after four weeks of exposure to HS extracts. (Kvam, Ofstad, & Iversen, 2000). The diuretic 
action HS extract is comparable to the most frequently used diuretics such as 
29 
hydrochlorothiazide (HCT) and furosemide used in the treatment of hypertensive 
individuals (Alarcón-Alonso et al., 2012). 
1.4.2.2 Hibiscus sabdariffa. L as a vasodilator. 
The vasodilating effect of HS extract is induced by the presence of a high 
concentration of anthocyanin bioactive compounds in the extract compared to other 
polyphenols. (Adegunloye et al., 1996) . The existence of anthocyanin in HS extract has 
been implicated in the activation of potassium ion (K+) channels, while activation of K+
causes the rapid efflux of K+ into the extracellular compartment and can stimulate 
hyperpolarization of the blood vessel membrane.  Hyperpolarization of the membrane 
inhibits cardiovascular activity  which can stimulate a significant reduction in blood 
pressure (Sarr et al., 2009). 
Similarly, HS has been shown to reduce BP and HR by inhibiting the SNS. It was 
investigated by a study in humans where an increased in sympathetic nervous activity and 
BP induced by cold pressor test (CPT) was subsequently inhibited after the administration 
of HS tablet (Aliyu, Oyeniyi, Mojiminiyi, Isezuo, & Alada, 2014). Another study 
confirmed the vasorelaxant effect of HS by its ability to induce the release of endothelium-
derived nitric oxide, which is a potent vasodilator and block the influx of calcium ions. 
This was confirmed in an animal model, where hypertensive rats were exposed to 0.3mg/ml 
of Hs extract daily for six weeks intervention period, and the vasodilating effect was 
observed in the aorta of the rats (Ajay, Chai, Mustafa, Gilani, & Mustafa, 2007). 
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1.4.2.3 Angiotensin-converting enzyme (ACE) inhibitor 
 The capability of HS extract to block the action of ACE is another hypotensive 
mechanism. The ACE is vital enzyme that facilitates the conversion of angiotensin-I to 
angiotensin-II in the RAAS. The anthocyanins in HS extract compete with the ACE 
binding site, thus preventing the formation of Ang II, which is a potent vasoconstrictor. 
The ability of HS extract to hinder the ACE activity was investigated in a randomized clinical 
trial where hypertensive patients (HTN stage 1 and 2) were exposed to either HS extract or 
25mg captopril twice daily (ACE inhibitor drug). The decreased in BP observed among 
patients exposed to anthocyanin-rich HS extract was similar to the BP reduction rates 
reported among patients on captopril (Ojeda et al., 2010).  
1.4.3 Toxicity of Hibiscus sabdariffa. L 
Despite the promising hypotensive benefit of HS and its outcome in minimizing the risks 
of developing cardiovascular diseases, its safety and contradictions among specific 
individuals should be clearly stated. Apart from consuming the pure HS extract, there are 
lots of commercially prepared herbal tea, where more than half of the total constituents 
consist of HS extract. While HS extract is considered to be safe and natural, the ingestion 
of  HS extract can as well be  harmful to individuals who are taken certain medications 
such as hydrochlorothiazide ( frequently used diuretics), acetaminophen, diclofenac, and 
other high risk groups (gravid ,lactating women and children). Some pre-clinical trials have 
reported a very low degree of acute toxicity when a high dose of HS extract is being 
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consumed. At the same time, exposure to more than 300mg/kg daily for a prolonged period 
of three months can result in significant hepatoxic effects. The lethal dose (LD50) of HS 
extract was confirmed in an in-vivo experimental animal model, where Wister albino rats 
exposed to high dosage of 300-2000mg/kg Hs extract per day for 3months showed a 
significant increase in liver enzymes and plasma creatinine, thus confirming the damaging 
effect on the liver (Fakeye, Pal, Bawankule, Yadav, & Khanuja, 2009). Similarly, in 
another animal study, rats exposed to a daily dose of 250-1000 mg/kg revealed no organ 
damage (Prommetta, Phivthong-ngam, Chaichantipyuth, Niwattisaiwong, & 
Lawanprasert, 2006). Based on several studies on HS toxicity dosage, it has been 
recommended that a maximum dose that is less than 1000mg/kg is considered safe and 
would not induce any organ damage in humans. 
1.5 Aim of the Study 
        The study aimed to examine the effect of Hibiscus sabdariffa tea and oolong tea on 
blood pressure and arterial stiffness in healthy human subjects after six weeks of the 
intervention period. We hypothesized that individuals who are exposed to a daily intake of 
HS tea would have a decrease in blood pressure and arterial stiffness after six weeks of the 
intervention period when compared to participants exposed to oolong tea. 
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1.6 Significance of the Study 
In the recent survey by the WHO, cardiovascular disease remains the number one 
cause of death in the United States, as well as low- and middle-income countries in the 
world.  High blood pressure has been considered as the major contributing factor 
responsible for CVDs. Despite the availability of antihypertensive drugs in many countries 
in the world today, more than 50% of hypertensive individuals were unable to control their 
HBP (Muntner et al., 2018). High costs of drugs, insufficient treatment due to non-
compliance, and undesirable side effects resulting from prolonged use of drugs have been 
implicated in poor management of hypertensive individuals. With the growing increase in 
uncontrolled HTN, the WHO has estimated the global annual death toll resulting from HBP 
would reach 23.5 million by the year 2030 if alternative treatment approaches are not being 
implemented (Organization, 2015). Thus, there is a need for urgent intervention to avert 
the current increasing rate of uncontrolled HBP in hypertensive individuals, hence the 
emerging use of Hibiscus sabdariffa and other complementary alternative therapies in the 
management of hypertension. 
Numerous studies have investigated the effect of HS extract/tea on reducing blood pressure 
both in humans and animals, while HS tea has also been reported to reduce arterial stiffness 
in animal and tissue models (GWALA, SİBUOR, Olabu, Pulei, & Julius, 2019). However, 
the effect of HS tea on arterial stiffness in humans is still unknown, to the best of our 




Forty-five healthy volunteers from Michigan Tech and Houghton community 
were assessed for eligibility into the study. Out of the 45 participants assessed, 
only 30 (17 males, 13 females) met all the inclusion criteria and were recruited into 
the study. The inclusion criteria for participation in this study were; men and women 
age 18-45 years, not pregnant, resting systolic blood pressure of at least 110 mmHg, 
body mass index (BMI) in the range 18.5-35kg/m2, not on any blood pressure 
medication, non-smokers and free of any acute or chronic metabolic diseases. 
Throughout the study, a total of 18 participants completed the study, while 12 
participants were lost to follow up due to the COVID-19 pandemic (Figure 2.1). 
    2.2  Study design and Procedures 
Initially, an orientation session was held at Michigan Tech’s Clinical and 
Applied Physiology lab (CAHP) following fasting for 5 hours by abstaining from food, 
caffeinated beverages, alcohol, and strenuous exercise. During the orientation, 
detailed study procedures and restrictions were explained to the volunteers. Questions 
to determine the subject’s eligibility were obtained using questionnaires; height, weight, 
and BMI were also measured and recorded. Potential participants were instructed to rest 
for 5 minutes before resting seated brachial blood pressure was measured in triplicate 




 All eligible participants signed informed written consent and information sheet 
before being officially enrolled in the study, and this study was approved by the 
Michigan Technological University Institutional Review Board (M1889). Eligible 
volunteers were scheduled for a full baseline testing session. 
Figure 2.1. Schematic illustration of study design and participant enrollment. 
The study was a randomized controlled clinical trial (RCT), subjects were randomized into 
one of two intervention groups: Hibiscus sabdariffa tea and oolong tea (control 
group). Before baseline testing, participants were instructed to fast overnight for a 
minimum of 12 hours, without food, drinks (alcohol, caffeine, except water), or 
exercise. Participants reported to SDC sleep research lab, where each was instructed to 
rest for 5 minutes before measuring three seated blood pressures. They were also told to 
lay supine for 5 minutes 
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Did not meet criteria. 
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before supine blood pressure was assessed in triplicate as well. Average values were 
recorded for both seated and supine blood pressures. Subjects in each group were instructed 
to consume the tea twice daily (one tea bag in the morning and one in the late 
evening/night) for six weeks. 
Dried calyces of organic Hibiscus sabdariffa tea and oolong tea leaves were 
commercially purchased, and 2g of dried leaves were measured and put in each of the 
teabags.  Also, commercially bagged Hibiscus sabdariffa and oolong Alvita brand teabags 
were purchased and allocated to only the first 4 HS participants and the first three oolong 
participants.  All the participants were instructed to steep 2 g of the teabag in 8 oz. of hot 
water, advised to abstain from drinking any other tea aside the one provided, but were not 
restricted from their usual dietary and exercise pattern throughout the study period. 
Participant’s compliance with tea intake at the end of the study was assessed by asking 
them to return unconsumed tea bags, and only readings of those that consumed more than 
90% of the tea bags were included in the final data analysis. Finally, volunteers were 
informed to report any unusual allergy or abnormal sensations to tea intake and stop 
drinking the tea immediately; however, none of the participants reported any adverse 
reaction to the tea. 
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2.3 Measurements 
2.3.1 Blood Pressure 
            The brachial blood pressure was measured, first in a seated position, and 
subsequently in a supine position with an automated sphygmomanometer (Omron HEM-
907XL, Omron Health Care, Kyoto, Japan). Participants were informed to refrain from 
talking while recording the blood pressure readings in both positions. Blood pressure 
readings were assessed three times, and average blood pressure readings for both seated 
and supine blood were recorded. The blood pressure measurement was standardized by 
using the same sphygmomanometer and participant’s right arm throughout the testing 
period. 
2.3.2 Pulse Wave Analysis 
            Before performing pulse wave analysis, subjects rested on a bed in the supine 
position for 5 minutes. The average supine blood pressure reading obtained was used to 
calibrate the SphygmoCor (SphygmoCor CPVH; AtCor Medical, Sydney, Australia). 
Radial applanation tonometry was performed non-invasively on each of the participants, 
which involved placing a tonometer probe on the radial artery and pressing the probe 
slightly against the carpal bone at the wrist. Ten strong radial pulse waves were captured 
by pressing/holding the probe for a few seconds on the right spot of the radial artery to 
provide trusted estimates of aortic blood pressure. This procedure was done twice to ensure 
consistency in the radial waves and aortic readings generated. An operator index greater 
80 was considered satisfactory throughout the testing period. 
The radial pulse wave generated was analyzed by the SphygmoCor software to 
provide estimates of aortic systolic blood pressure (SAP), diastolic blood pressure (DAP), 
mean aortic pressure (MAP) and pulse pressure (PP). Also, aortic augmentation index 
(AIx) was calculated automatically by the SphygmoCor software based on the 
characteristics of the pulse waves. The procedure was standardized by excluding any 
participant with aortic pulse pressure greater than 50 mmHg, as these individuals may be 
more susceptible to plaques that could potentially become dislodged with force (Roman et 
al., 2007).  
2.3.3 Pulse Wave Velocity 
             The pulse wave velocity was determined by non-invasive applanation tonometry. 
Using a three-lead electrocardiogram (ECG) involving the use of three surface electrodes, 
two electrodes were placed at the left and right side of the shoulder region, while the last 
electrode was placed below the rib cage of the left side of the participants. The distance 
(mm) between the pulse site in the carotid artery and the suprasternal notch was measured
with a tape. At the same time, the second distance measured from the femoral pulse located 
in the femoral artery and the suprasternal notch was also recorded.  Central arterial stiffness 
(carotid-femoral) was measured by placing the tonometer on the pulse site first on the 
carotid artery and subsequently on the femoral artery on the first trial, while in the opposite 
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direction on the second trial. The SphygmoCor software utilizes the measured distance and 
the time delay from the appearance of the incident wave in the heart and the arrival of the 
reflected wave back at the pulse site for the estimation of carotid-femoral pulse wave 
velocity (cfPWV).  The test was performed in duplicate to standardize the procedure, and 
readings with a standard deviation of ≤ 10% were included in the final data analysis. 
2.4 Statistical Analyses 
Statistical analysis of the data was performed using IBM SPSS statistics software 
(SPSS version 20.0).  Analysis of variance (2 x 2 repeated-measures ANOVA) was used 
to determine the time and treatment effects on tested variables between the two groups. 
Welch two-sample t-test was used to compare the baseline variables due to the unequal 
sample size between the two groups. The cfPWV of two participants was not measured, 
while one subject did not have recordings for PWA, and was excluded in the final data 
analysis. The results were expressed as mean values ± standard deviation (SD), and P-value 
< 0.05 was considered significant. 
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3 Results 
3.1 Participants Characteristics 
The baseline demographic and clinical characteristics of the study participants are 
shown in Table 3.1.  The mean age of the participants in the HS group and control group 
was 32 ± 10 years and 27 ± 5, respectively. Generally, there was no significant difference 
in the demographic data and tested clinical variables between the two groups at baseline (P > 0.05).
3.2 Tested Clinical Variables 
The within-group and between-group comparisons were analyzed on the following 
clinical variables: SBP, DBP, HR, AIx, and cfPWV before and after the intervention. A 
reduction in the brachial seated blood pressure was observed within the HS group, with a 
decrease in post-intervention mean SBP (-4 mmHg) and DBP (-3 mmHg) when compared 
with pre-intervention values. Also, the oolong tea (control) induces reductions in SBP (-
4mmHg) and DBP (-9.06 mmHg) (Figure 3.1A and B). A 2 x2 repeated-measures ANOVA 
between the group revealed a significant time effect for both SBP (P = 0.02) and DBP (P 
= 0001). However, there was no significant time by group effect; a reduction in blood 
pressure was also observed in the control group.  
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Table 3.1. Baseline Demographic and Clinical Characteristics of the Participants    
Values are means ± standard deviation (SD); n: number of participants; HS: Hibiscus 
sabdariffa; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood 
pressure; HR: Heart rate; AIx@HR75: Aortic augmentation index normalized to 75 
heartbeats; cfPWV: Carotid-femoral pulse wave velocity. P-value obtained from Welch 
two Sample t-test for baseline comparison between the two groups. 





Age (yrs.) 32 ± 10 27 ± 5 0.17 
Sex (men/women), n 8/3 5/2 
Weight (kg) 82 ± 18 84 ± 16 0.79 
Height (cm) 176 ± 10 172 ± 10 0.58 
BMI (kg/m2) 26 ± 3 28 ± 4 0.45 
Seated SBP (mmHg) 123 ± 7 122 ± 9 0.81 
Seated DBP (mmHg) 74 ± 7 70± 9 0.36 
Supine SBP (mmHg) 121 ± 7 118 ± 5 0.54 
Supine DBP (mmHg) 70 ± 7 64 ± 5 0.06 
HR (beats/mins) 64 ± 11 59 ± 10 0.32 
AIx@HR75 (%) 3.1 ± 19.0 -0.6 ± 10 0.35 
cfPWV (m/s) 6.2 ±0.9 5.5 ± 0.4 0.05 
42 
Figure 3.1.  A: comparing mean SBP (systolic blood pressure) pre- vs. 6weeks post- 
intervention; B: mean DBP (diastolic blood pressure) for pre -vs post intervention. A 2 x2 
repeated-measures ANOVA between groups revealed significant time effect (P = 0.02; P 
= 0.001) for SBP and DBP respectively, and no significant time by group effect (P > 0.05).  
Results are mean ± standard deviation (SD).   
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Figure 3.2: Comparing the heart rate (HR) before and after intervention between the two 
groups. * Significant difference within HS group (P < 0.05). No significant difference 
within control (P = 0.69). Repeated ANOVA between the groups revealed a significant 
time effect on HR (P =0.028). Results are mean ± standard deviation (SD).   
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Figure 3.3:  Carotid-femoral pulse wave velocity (cfPWV) before and after intervention 
between HS and control groups. Repeated ANOVA revealed no significant time effect (P= 
0.44) and time by treatment effect between groups (P =0.35). All values are mean ± 
standard deviation (SD) 
Also, there was a reduction in HR in both groups when compared with pre-
intervention values (Figure 3.2). However, only the HS tea intervention induced a 
significant decrease in HR (P = 0.01) when compared with oolong tea (P= 149), as depicted 
in figure 3.2. Furthermore, the carotid-femoral pulse wave velocity (cfPWV) comparison 
before and after tea intervention showed a slight reduction in cfPWV (-0.5m/s) in the HS 
group, while an increase of (+0.3m/s) was observed in the control group (Figure 3.3). 
Although, we did not find any significant time (P= 0.44) and time* treatment group (P= 
0.35) effect in both case and the control groups. 
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4 Discussion 
In this study, we investigated the effects of Hibiscus sabdariffa and Oolong tea on 
blood pressure and arterial stiffness in healthy adults. The results showed that the six weeks 
tea intervention had a significant positive impact on SBP, DBP, and heart rate.  However, 
there was no significant time by treatment group effect on the blood pressure, as both SBP 
and DBP were also decreased in the Oolong tea group after six weeks of intervention. The 
HS tea consumption resulted in a significant decrease in HR, while the observed reduction 
in the control group was not statistically significant. To our knowledge, this is the first 
study to investigate the effect of HS tea consumption on central arterial stiffness in humans. 
There was a slight decrease in the mean cfPWV value within the HS group when compared 
with the control, but the reduction was not statistically significant. 
 The partial oxidation and fermentation of Camellia sinensis plant leaves results in the 
production of Oolong tea. The concentration of caffeine in the tea derived from Camellia 
sinensis depends on the method of cultivation and intensity of oxidation during processing. 
While the caffeine content in oolong tea is considerably small when compared to black tea, 
although excessive consumption could also stimulate an acute rise in blood pressure. 
Several clinical trials on the antihypertensive effect of oolong tea and other tea derived 
from Camellia sinensis (green and black tea) reported convincing data that need to be 
verified and confirmed. In this current study, both the HS and Oolong tea (control) lowered 
blood pressure. The results from this study are in agreement with most of the previous 
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clinical and experimental studies on antihypertensive effects of HS tea. In a clinical trial, 
where the impact of HS tea on stage 1 hypertensive patients was investigated, a decrease 
in blood pressure was reported in both the case and the control groups (Jalalyazdi et al., 
2019). In another trial, the effect of HS tea consumption on patients with mild hypertension 
resulted in significant reductions in SBP, DBP, and MAP when consumed thrice daily for 
six weeks (McKay et al., 2009).  A meta-analysis of 13 RCTs on the effect of green tea 
consumption on blood pressure showed a significant decrease in SBP and DBP by 1.98 
mmHg and 1.92 mmHg, respectively, when compared to the control group (Peng et al., 
2014).  
Contrary to our study, is a RCT that compared the antihypertensive effect of HS tea 
with green tea in healthy adult men. The study concluded that the daily administration of 
450mg of HS could induce a significant reduction in only SBP when compared with green 
tea,  the study did not report any significant difference in DBP in either the HS and green 
tea intervention (Kafeshani et al., 2017). While, another meta-analysis of 5 RCTs showed 
no significant changes in the blood pressure after about four weeks of oolong tea 
consumption (Liu et al., 2014).    
The significant decrease in HR within the participants exposed to HS tea when 
compared to control in this study is similar to the reports obtained from another randomized 
clinical trial. In the previous study, a significant reduction in HR was observed after the 
administration of 15mg/kg of HS extract to individuals with increased HR-induced by 
hand-grip exercise (HE) and cold pressor test (Aliyu et al., 2014). Also, reports from an 
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animal study confirmed the HR reduction induced by HS extract. Chronic ingestion of HS 
extract (250mg/kg/day) into renovascular hypertensive-induced rats for eight weeks 
resulted in a significant decrease in HR (Odigie, Ettarh, & Adigun, 2003). The probable 
mechanism of reducing HR has been associated with HS’s ability to inhibit sympathetic 
nerve activity. It was reported that the activation of SNS induced by CPT, which led to the 
stimulation of pain, cold receptors, constriction of blood vessels, caused an increase in HR. 
The subsequent administration of HS extract counteracted the activated SN activity, 
thereby mediating the reduction in HR back to normal (Aliyu et al., 2014).  
 Despite the numerous cardioprotective effects of HS reported in previous studies, the 
specific antihypertensive mechanisms of HS are not fully understood. Different 
antihypertensive mechanisms have been reported; regulating serum electrolyte due to its 
diuretic effect (Herrera-Arellano et al., 2007), ACE inhibitory activity (Ojeda et al., 2010), 
inhibition of SNS  and regulation of blood lipids (Morales‐Luna et al., 2019), which are all 
involved in the pathogenesis of hypertension Recently, the anthocyanin which is the 
bioactive compound in HS extract has been reportedly linked to most of the 
antihypertensive mechanisms of HS. This was confirmed in an animal study where the 
effect of dried HS calyx was compared with HS anthocyanin (HSA) extract on spontaneous 
hypertensive rats. It was indicated that long-term ingestion (10 weeks) of HSA resulted in 
a significant reduction in SBP, DBP, and left ventricular mass when compared to the whole 
HS calyx (Inuwa et al., 2012).  Similarly, the probable antihypertensive mechanism of 
oolong tea can be linked to the concentration of “catechins,” which is the bioactive 
48 
compound in tea. Catechins have been shown to induce the release of NO from the 
endothelium, which can inhibit the constriction of blood vessels. Extracts from Camellia 
sinensis lowers blood pressure by enhancing the production of antioxidant enzymes that 
inactivate reactive oxygen species (ROS). The antioxidant enzymes includes; catalase, 
glutathione peroxidase, glutathione reductase and superoxide dismutase (Thomson, Al-
Qattan, Mansour, & Ali, 2012) 
As previously stated, arterial stiffness is one of the most common mechanisms that 
could contribute to the development of hypertension, increased arterial stiffness has been 
associated with aging, high blood pressure and increased risk of cardiovascular diseases. 
In this study, we investigated the effect of HS tea on arterial stiffness as a probable 
mechanism by which HS tea could decrease blood pressure. While the observed slight 
decrease in cfPWV (-0.5m/s) was not statistically significant with our limited sample-size, 
the -0.5m/s reduction could be clinically significant as 1m/s reduction in cfPWV could all 
reduce CVD-induced mortality by 15% (Vlachopoulos, Aznaouridis, & Stefanadis, 2010). 
Thus, the 0.5 m/s reduction after HS could indicate the risk for mortality is reduced by 
approximately 7.5%. 
4.1 Limitations 
Generally, the variability in response reported in this study and some previous HS 
clinical trials have been linked to lack of standardization in the amount of HS consumed, 
different methods/conditions used in the preparation of HS (infusion, extraction or 
decoctions) and the methods of use by the trial participants (a varying amount of water and 
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temperature condition). All those factors listed above would affect the dose of the bioactive 
compound (anthocyanins) in HS given to trial participants. 
One major limitation of this study was our small size. The sample size was 
considerably small due to participants who were lost to follow-up because of the COVID-
19 pandemic. The imbalance in the number of participants between the HS and the control 
groups was a concern, as more of the participants lost to follow-up were in the control 
group. Also, the true blinding of our treatments was not feasible because of the distinct 
tastes of HS and the oolong tea used as control. Furthermore, in this trial, we used dried 
calyx of HS, measured, and packed in the teabags, we were unable to extract and 
standardize the amount of the active anthocyanins in the HS tea consumed by the 
participants, and thus could lead to some variability in the doses of bioactive compound. 
Lastly, most of the participants recruited for this study were volunteers studying at the 
university, so we were unable to completely exclude other confounding factors such as 
stress, diets, and exercise conditions that could potentially influence the cardiovascular 
measurements. 
4.2 Future Directions 
Future studies on the antihypertensive effects of HS on humans should be well 
standardized by extracting the anthocyanin bioactive compound from the dried calyx. The 
quantification of anthocyanin doses by high-performance liquid chromatography coupled 
with mass spectrometry (HPLC-MS) before administering it to trial participants is highly 
50 
recommended to achieve the desired hypotensive effects and at the same time preventing 
HS overdose that could potentially be toxic to some organs in the body.  Previous studies 
on the HPLC analysis of HS have shown the presence of four different types of 
anthocyanins in HS extract; however, a large amount of delphinidin-3-O- sambubioside 
(Dp-samb) has been reported. As such, we recommend further fractionation of HS to 
separate the Dp-samb from other anthocyanins in the HS extract before consumption to 
achieve maximum benefits.  Also, more robust, randomized controlled clinical trials with 
a high dosage of Dp-samb targeted for a longer duration of intervention would be desirable 
to achieve the beneficial effects of HS extract in the treatment of hypertension. 
The selection of the most desirable control tea that would not have any effect on the 
cardiovascular system was a challenge to our study and most of the previous RCTs.  While 
trying to select a tea that would have the same color and similar sour taste like HS tea to 
ensure blinding of the participants, it is also imperative to choose a tea that lacks the 
bioactive anthocyanin compounds found in HS tea. We conducted a small preliminary 
study, by randomizing four participants to a peach control tea, which has a light red color 
and somewhat sour taste. It was observed that all the tested cardiovascular variables remain 
unchanged after six weeks of peach tea consumption (Figure 3.4 A-D). 
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Figure 3.4 A: Comparing systolic blood pressure (SBP), B: Diastolic blood pressure 
(DBP), C: Aortic augmentation index (AIX), and D: Carotid-femoral pulse wave velocity 
(cfPWV) before and after peach tea consumption. Results are mean ±SD. 
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In figure 3.4 above, there were no changes in all the measured cardiovascular 
variables after six weeks of drinking peach tea when compared to baseline measurements. 
Based on these promising preliminary findings, we recommend the use of peach tea as a 
reliable control in future tea studies. RCTs with an active control protocol would be 
superior to many of the previous studies on tea that have used a wait-list period in place of 
randomization into an active control group. 
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A. Appendix A- Raw Data
A.1 Participant’s Baseline Characteristics 
Table A.1: Baseline Demographics and Clinical Characteristics Raw Data 
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A.2 Blood Pressure Measurements 
Table A.2. Pre and Post Intervention Blood Pressure Readings Raw Data 








Pre - PP Post- PP 
1 124 68 125 66 56 59 
2 110 70 121 67 40 54 
3 130 89 121 79 41 42 
4 130 80 116 79 51 37 
5 127 69 124 68 58 60 
6 123 81 120 71 42 49 
7 130 75 128 77 55 51 
8 126 70 120 70 56 50 
9 118 71 112 71 47 41 
10 126 66 128 71 60 57 
11 114 71 99 62 43 37 
12 110 68 116 66 42 50 
13 118 73 111 69 45 42 
14 137 75 127 67 62 60 
15 129 80 126 77 49 49 
16 114 74 111 69 40 42 
17 122 66 117 58 56 59 
18 127 53 120 46 74 74 
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19 114 68 N/A N/A 46 N/A 
20 127 77 N/A N/A 50 N/A 
21 118 80 N/A N/A 38 N/A 
22 123 71 N/A N/A 52 N/A 
23 112 58 N/A N/A 54 N/A 
24 129 86 N/A N/A 43 N/A 
25 114 73 N/A N/A 41 N/A 
26 111 66 N/A N/A 45 N/A 
27 124 73 N/A N/A 51 N/A 
28 117 70 N/A N/A 47 N/A 
29 124 75 N/A N/A 49 N/A 
30 122 71 N/A N/A 51 N/A 
SBP- Systolic blood pressure (mmHg); DBP- Diastolic blood pressure (mmHg); PP- 
Pulse pressure; N/A -missing values due to lack of follow-up. 
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A.3  Central Hemodynamics Measurements



















1 91 64 101 64 2.5 8 5.1 5.2 
2 97 65 97 66 11.5 11 5.9 4.6 
3 121 88 113 79 23 25 N/A N/A 
4 119 78 114 84 38 31 6.2 6.2 
5 105 63 103 65 -13 -10 4.8 6.2 
6 N/A N/A N/A N/A N/A NA 7.9 6.1 
7 104 71 106 67 5.5 6 7.2 6.8 
8 102 71 99 71 - 23 5.7 6.6 
9 107 72 100 71 13 2 6.2 5.6 
10 104 66 104 72 -22 -10 6.5 5.3 
11 97 53 86 63 -14 -15 6.2 5.3 
12 97 69 91 56 11.5 7 5.2 4.9 
13 102 74 88 64 1..0 2 4.8 4.8 
14 101 64 110 170 2 5 5.2 5.4 
15 95 69 94 66 3.5 0 N/A NA 
16 99 68 100 67 6 9.5 6.1 5.6 
17 99 66 92 58 -17 -30 5.6 6.1 
18 97 53 95 47 -11 -1 5.8 6.1 
19 101 67 NA NA NA NA NA NA 
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20 106 69 NA NA NA NA NA NA 
21 104 76 NA NA NA NA NA NA 
22 94 65 NA NA NA NA NA NA 
23 81 49 NA NA NA NA NA NA 
24 103 77 NA NA NA NA NA NA 
25 96 63 NA NA NA NA NA NA 
26 88 57 NA NA NA NA NA NA 
27 87 59 NA NA NA NA NA NA 
28 94 55 NA NA NA NA NA NA 
29 102 78 NA NA NA NA NA NA 
30 99 61 NA NA NA NA NA NA 
SAP -Systolic aortic pressure; DAP- Diastolic aortic pressure; AIX@HR75- Aortic 
augmentation index in 75beats; cfPWV- Carotid-femoral pulse wave velocity; N/A -
missing values due to absence of follow up 
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A.4.  Peach tea Control Raw Data for the Pilot study





















1 117 66 114 69 13 20 5 5 
2 118 68 119 69 24 17 6.6 6.6 
3 122 74 127 72 2.5 12.5 5.9 6.2 
4 113 65 116 70 8 7 7.1 6.9 
SBP-Systolic blood pressure; DBP-Diastolic blood pressure; Aix- Aortic 
augmentation index, cfPWV- Carotid-femoral pulse wave velocity. 
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B APPENDIX B- Statistical Analyses 
Table B.1 a Descriptive Statistics Of SBP 
Treatment Mean Std. 
Deviation 
N 
Pre_SBP Hibiscus 123.4545 6.74335 11 
Camellia_sinensis 122.4286 9.32483 7 
Total 123.0556 7.59622 18 
Post_SBP Hibiscus 119.4545 8.29896 11 
Camellia_sinensis 118.2857 6.47339 7 
Total 119.0000 7.45970 18 
Table B.1b- Multivariate Tests by 2x2 Repeated-measures ANOVA 
     Effect Value F Hypothesis df Error df Sig. 
time Pillai's Trace .288 6.457b 1.000 16.000 .022 
         Wilks' Lambda .712 6.457b 1.000 16.000 .022 
       Hotelling's Trace .404 6.457b 1.000 16.000 .022 
   Roy's Largest Root .404 6.457b 1.000 16.000 .022 
time * Treatment
Pillai's Trace 
.000 .002b 1.000 16.000 .965 
Wilks' Lambda 1.000 .002b 1.000 16.000 .965 
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Hotelling's Trace .000 .002b 1.000 16.000 .965 
Table B.1c – Tests of Within-Subjects Effects 
Measure: MEASURE_1 
Source 
Type III Sum 
of Squares 
Df Mean Square F 
time Sphericity Assumed 141.821 1 141.821 6.457 
Greenhouse-Geisser 141.821 1.000 141.821 6.457 
Huynh-Feldt 141.821 1.000 141.821 6.457 
Lower-bound 141.821 1.000 141.821 6.457 
time * Treatment Sphericity 
Assumed 
.044 1 .044 .002 
Greenhouse-Geisser .044 1.000 .044 .002 
Huynh-Feldt .044 1.000 .044 .002 
Lower-bound .044 1.000 .044 .002 
Error(time) Sphericity Assumed 351.429 16 21.964 
Greenhouse-Geisser 351.429 16.000 21.964 
Huynh-Feldt 351.429 16.000 21.964 
Lower-bound 351.429 16.000 21.964 
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Table B.1d: Test of Between- Subjects Effect 
Source 
Type III Sum 
of Squares 
df Mean Square F Sig. 
Partial Eta 
Squared 
Intercept 500268.081 1 500268.081 5114.010 .000 .997 
Treatment 10.303 1 10.303 .105 .750 .007 
Error 1565.169 16 97.823 
Table B.2: Descriptive Statistics of DBP 
Treatment Mean Std. 
Deviation 
N 
Pre_DBP Hibiscus 73.6364 6.96093 11 
Camellia_sinensis 69.8571 8.74507 7 
Total 72.1667 7.68689 18 
Post_DBP Hibiscus 71.0000 5.44059 11 
Camellia_sinensis 64.5714 9.91392 7 
Total 68.5000 7.90569 18 
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Table B.2a: ANOVA for DBP 
Effect Value F Hypothesis 
df 
Error df Sig. 
time Pillai's Trace .486 15.126b 1.000 16.000 .001 
Wilks' Lambda .514 15.126b 1.000 16.000 .001 
Hotelling's Trace .945 15.126b 1.000 16.000 .001 
Roy's Largest Root .945 15.126b 1.000 16.000 .001 
time * Treatment Pillai's Trace .096 1.692b 1.000 16.000 .212 
Wilks' Lambda .904 1.692b 1.000 16.000 .212 
Hotelling's Trace .106 1.692b 1.000 16.000 .212 
Roy's Largest Root .106 1.692b 1.000 16.000 .212 
Table B.2b:  Tests of Between-Subjects Effects 
Source 
Type III Sum 
of Squares 
df Mean Square F Sig. 
Partial Eta 
Squared 
Intercept 166570.759 1 166570.759 1579.684 .000 .990 
Treatment 222.870 1 222.870 2.114 .165 .117 
Error 1687.130 16 105.446 
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     Table B.3a- Descriptive Statistics for HR 
Treatment Mean Std. 
Deviation 
N 
Pre_HR Hibiscus 64.2727 10.84519 11 
Camellia_sinensis 59.1429 9.90671 7 
Total 62.2778 10.50941 18 
Post_HR Hibiscus 58.0000 9.02219 11 
Camellia_sinensis 57.7143 11.77164 7 
Total 57.8889 9.83923 18 








time Pillai's Trace .266 5.800 .619 
Wilks' Lambda .266 5.800 .619 
Hotelling's Trace .266 5.800 .619 
Roy's Largest Root .266 5.800 .619 
time * Treatment Pillai's Trace .125 2.295 .297 
Wilks' Lambda .125 2.295 .297 
Hotelling's Trace .125 2.295 .297 
Roy's Largest Root .125 2.295 .297 
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time Pillai's Trace .266 5.800 .619 
Wilks' Lambda .266 5.800 .619 
Hotelling's Trace .266 5.800 .619 
Roy's Largest Root .266 5.800 .619 
time * Treatment Pillai's Trace .125 2.295 .297 
Wilks' Lambda .125 2.295 .297 
Hotelling's Trace .125 2.295 .297 
Roy's Largest Root .125 2.295 .297 
   Table B.3d -Tests of Within-Subjects Effect 
Source 
Type III Sum 
of Squares 
df Mean Square F 
time Sphericity Assumed 126.858 1 126.858 5.800 
Greenhouse-Geisser 126.858 1.000 126.858 5.800 
Huynh-Feldt 126.858 1.000 126.858 5.800 
Lower-bound 126.858 1.000 126.858 5.800 
time * Treatment Sphericity 
Assumed 
50.191 1 50.191 2.295 
Greenhouse-Geisser 50.191 1.000 50.191 2.295 
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Huynh-Feldt 50.191 1.000 50.191 2.295 
Lower-bound 50.191 1.000 50.191 2.295 
Error(time) Sphericity Assumed 349.948 16 21.872 
Greenhouse-Geisser 349.948 16.000 21.872 
Huynh-Feldt 349.948 16.000 21.872 
Lower-bound 349.948 16.000 21.872 
Table B.4a -Descriptive Statistics for Carotid-femoral Pulse wave velocity (cfPWV) 
Treatment Mean Std. 
Deviation 
N 
Pre_cfPWV Hibiscus 6.1700 .91171 10 
Camellia_sinensis 5.4500 .47223 6 
Total 5.9000 .83825 16 
Post_cfPWV Hibiscus 5.7900 .69833 10 
Camellia_sinensis 5.4833 .56362 6 
Total 5.6750 .64962 16 
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   Table B.4a – ANOVA Test for cfPWV 
Effect Value F Hypothesis df Error 
df 
Sig. 
time Pillai's Trace .044 .647b 1.000 14.000 .435 
Wilks' Lambda .956 .647b 1.000 14.000 .435 
Hotelling's Trace .046 .647b 1.000 14.000 .435 
Roy's Largest Root .046 .647b 1.000 14.000 .435 
time * Treatment Pillai's Trace .062 .920b 1.000 14.000 .354 
Wilks' Lambda .938 .920b 1.000 14.000 .354 
Hotelling's Trace .066 .920b 1.000 14.000 .354 
Roy's Largest Root .066 .920b 1.000 14.000 .354 
Table B.4b – Tests of Within-Subjects Effects 
Source 
Type III Sum 
of Squares 
df Mean Square F 
time Sphericity Assumed .225 1 .225 .647 
Greenhouse-Geisser .225 1.000 .225 .647 
Huynh-Feldt .225 1.000 .225 .647 
Two by two -repeated measures ANOVA 
for testing the time effect and time b                                                       y treatment group 
effect for the carotid-femoral pulse wave velocity
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Lower-bound .225 1.000 .225 .647 
time * Treatment Sphericity 
Assumed 
.320 1 .320 .920 
Greenhouse-Geisser .320 1.000 .320 .920 
Huynh-Feldt .320 1.000 .320 .920 
Lower-bound .320 1.000 .320 .920 
Error(time) Sphericity Assumed 4.875 14 .348 
Greenhouse-Geisser 4.875 14.000 .348 
Huynh-Feldt 4.875 14.000 .348 
Lower-bound 4.875 14.000 .348 
Table B.5c – Tests of Within-Subjects Contrast 
Source time 
Type III Sum 
of Squares 
df Mean Square F Sig. 
time Linear .225 1 .225 .647 .435 
time * Treatment
Linear 
.320 1 .320 .920 .354 
Error(time) Linear 4.875 14 .348 
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Table B.5d – Tests of Between-Subjects Effects 
Source time 
Type III Sum 
of Squares 
df Mean Square F Sig. 
time Linear .225 1 .225 .647 .435 
time * Treatment
Linear 
.320 1 .320 .920 .354 
Error(time) Linear 4.875 14 .348 
Table showing the time effect and time by treatment group effect between the subjects  
